GSK and Ionis break new ground in Hepatitis B with positive Phase 3 results
Ionis Pharmaceuticals (NASDAQ:IONS) shares hovered near 52-week highs Wednesday after partner GSK (NYSE:GSK) announced that its experimental drug, bepirovirsen, successfully met the primary endpoints in two pivotal Phase 3 trials, B-Well 1 and B-Well 2.



-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)


-640x358.jpg&w=3840&q=75)

